BusinessMelinta Therapeutics Presents Outcomes of Baxdela Treatment of Gram-Positive and Gram-Negative Pathogens at IDWeekBy Nasdaq OMXOct 4, 2017, 5:14 PM UTC
BusinessMelinta Therapeutics Presenting Detailed Analyses from Baxdela Phase 3 ABSSSI Trials and In Vitro Performance against Isolates of Resistant CABP and other InfectionsBy Nasdaq OMXSep 25, 2017, 12:01 PM UTC
BusinessTetraphase Pharmaceuticals Announces Eight Data Presentations at IDWeek 2016By Nasdaq OMXOct 26, 2016, 12:05 PM UTC
BusinessTetraphase Pharmaceuticals Announces Eight Data Presentations at IDWeek 2016By Nasdaq OMXOct 26, 2016, 12:05 PM UTC
BusinessMelinta Therapeutics’ Baxdela™ to be Featured in Six Poster Presentations at IDWeek 2016™By Nasdaq OMXOct 26, 2016, 12:00 PM UTC
